Detail Benefits, cost requirements and cost-effectiveness of the hpv16, 18 vaccine for cervical cancer prevention in developing countries: policy implications.   Oleh:  Goldie, Sue J. ; O'Shea, Michael ; Sun-Young, Kim ; Diaz, Mireia Jenis: Article from Books Dalam koleksi: Reproductive health matters: reproductive cancers, page 86. Topik: Cervical Cancer; Human Papillomavirus Vaccine; Cost-Effectiveness; Priority Setting; Health Policy and Programmes Ketersediaan Perpustakaan PKPM Nomor Panggil: 614:312.31 REP Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada     Lihat Detail Induk Isi artikel Approximately 70% of cases of cervical of cervical cancer worldwide are caused by genotypes 16 and 18 of human papillomavirus (HPV), which is sexually transmitted. With the availability of an effective vaccine against these HPV types, there is real hope for reducing the global burden of cervical cancer in developing countries. Stakeholders faced with decisions about where to invest money to improve health must consider the burden of disease caused by cervical cancer relative to other priorities and the comparative benefits of different intereventions. We conducted a series of analyses to obtain information for agencies drafting immunisation policy recommendations, financing coordination mechanisms, and country decision-makers on the benefits, cost requirements and cost-effectiveness of the HPV 16, 18 vaccine. Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved